Eli Lilly: FDA approves apnea treatment

(CercleFinance.com) - The FDA approves Zepbound® (tirzepatide) as the first and only prescription drug for moderate-to-severe obstructive sleep apnea in obese adults.


Zepbound can help adults with moderate-to-severe obstructive sleep apnea and obesity improve their sleep disorder. It should be used with a low-calorie diet and increased physical activity.

' It's important to understand the symptoms of OSA and to know that treatments are available, including new options like Zepbound. We hope this will spark more meaningful conversations between patients and healthcare providers and, ultimately, lead to better health outcomes' said Julie Flygare, J.D., President and CEO of Project Sleep.

OSA is a sleep-related breathing disorder characterized by complete or partial collapse of the upper airway during sleep, which can lead to pauses in breathing (apnea) or shallow breathing (hypopnea) and a potential decrease in oxygen saturation and/or awakening from sleep.

Zepbound is the first drug to significantly improve moderate to severe OSA and aid long-term weight loss in obese adults. Nearly half of patients in clinical trials experienced such improvements that they no longer had symptoms associated with OSA, marking a crucial step in reducing the burden of this disease and its interconnected health challenges' said Patrik Jonsson, Executive Vice President and President of Lilly Cardiometabolic Health and Lilly USA.

Copyright (c) 2024 CercleFinance.com. All rights reserved.